Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of LB1148 in Accelerating the Time to Return of Bowel Function in Subjects Undergoing Planned Bowel Resection

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of LB1148 in Accelerating the Time to Return of Bowel Function in Subjects Undergoing Planned Bowel Resection

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tranexamic acid (Primary)
  • Indications Postoperative ileus
  • Focus Registrational; Therapeutic Use
  • Acronyms INTEGRITY
  • Sponsors Palisade Bio

Most Recent Events

  • 17 Jun 2024 Status changed from active, no longer recruiting to discontinued. (Reason the study was stopped: Company decision)
  • 15 Nov 2022 Status changed from recruiting to active, no longer recruiting.
  • 14 Nov 2022 According to a Palisade Bio media release, company's Board commenced a thorough review of ongoing clinical programs of LB1148. The Company believes that this trial protocol requires additional standardization across sites and further clarification in the definition of endpoints to permit an adequate assessment of the efficacy of LB1148 to recover GI function.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top